CDEK
← All drugs Report issue

trehalose

Small moleculeexperimental

Trehalose is a sugar derived from two molecules of glucose. Trehalose is a disaccharide formed by a 1,1-glycosidic bond between two α-glucose units. It is found in nature as a disaccharide and also as a monomer in some polymers. Two other stereoisomers exist: α,β-trehalose, also called neotrehalose, and β,β-trehalose, also called isotrehalose. Neither of these alternate isomers has been isolated from living organisms, but isotrehalose has been found in starch hydroisolates. Some bacteria, fungi, plants and invertebrate animals synthesize it as a source of energy, and to survive freezing and lack of water. — Wikipedia

Clinical trial activity

31 trials · 32 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
13
Phase 3
8
Phase 4
4

Earliest trial started Jul 1, 2011 (NCT01746602)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetUnclear

    Unclear

Chemistry & pharmacology

Loading structure…

SMILES

OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
Mol. weight
342.3 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cabaletta
  • cabaletta
  • cabaletta
  • trehalose
  • trehalose
  • trehalose

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07263880Phase 1/Phase 2 (Phase 2)Dec 1, 2025Azienda Ospedaliera San Giovanni Addolorata, University of Roma La Sapienza
NCT06655441Phase 4Jan 1, 2025Southern California College of Optometry at Marshall B. Ketchum University
NCT06726902N/AMar 3, 2024Alexandria University
NCT06163989N/AFeb 1, 2024Aston University
NCT05990712Phase 4Sep 1, 2023Uptown Eye Specialists
NCT05743764Phase 3Mar 1, 2023Huons Co.,Ltd.
NCT05332678Phase 2Jan 31, 2023Seelos Therapeutics
NCT05593549Early Phase 1 (Phase 1)Jan 1, 2023Medical College of Wisconsin
NCT05333211Phase 1/Phase 2 (Phase 2)Jun 30, 2022ChitogenX Inc
NCT05490563Phase 2/Phase 3 (Phase 3)Jun 3, 2022Seelos Therapeutics
NCT05355064Phase 4May 31, 2022Neuromed IRCCS
NCT05356728N/AMar 11, 2022Laboratoires Thea, The Norwegian Dry Eye Clinic
NCT05136885Phase 2/Phase 3 (Phase 3)Dec 31, 2021Harvard University, Seelos Therapeutics
NCT04704518Phase 4May 1, 2021Laboratorios Sophia S.A de C.V.
NCT04663854Phase 1Aug 20, 2020Mashhad University of Medical Sciences
NCT04399265Early Phase 1 (Phase 1)Mar 2, 2020National University of Malaysia
NCT04061070N/AOct 1, 2019University of Roma La Sapienza
NCT03700424Phase 2Jun 30, 2019Government of Iran, Mashhad University of Medical Sciences
NCT04384991Phase 3May 3, 2019Huons Co.,Ltd.
NCT04426149N/AMar 7, 2018National University of Malaysia
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (32)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bioblast Pharma Ltd.For profit5532014
Seelos TherapeuticsFor profit4332021
Huons Co.,Ltd.For profit3312018
Harvard UniversityAcademic/Hospital2122021
Mashhad University of Medical SciencesAcademic/Hospital2222019
McGill UniversityAcademic/Hospital2012014
National University of MalaysiaAcademic/Hospital2222018
University of Roma La SapienzaAcademic/Hospital2122019
Alexandria UniversityAcademic/Hospital1112024
Aston UniversityAcademic/Hospital1112024
Azienda Ospedaliera San Giovanni AddolorataAcademic/Hospital1112025
Catholic University of KoreaAcademic/Hospital1012018
Centro de Investigación Biomédica en Red (CIBER)Academic/Hospital1112016
ChitogenX IncFor profit1112022
Government of IranGovernment1012019
Hebrew UniversityAcademic/Hospital1012014
Laboratoires TheaFor profit1012022
Laboratorios Sophia S.A de C.V.For profit1112021
Medical College of WisconsinAcademic/Hospital1112023
National Institute of Neurological Disorders and Stroke (NINDS)Government101—
32 organizations
Page 1 / 2